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Abstract
Background: The 2009 US Preventive Services Task Force breast cancer screening update recommended against routine
screening mammography for women aged 40–49; confusion and release of conflicting guidelines followed. We examined
the impact of the USPSTF update on population-level screening mammography rates in women ages 40–49.
Methods and Findings: We conducted a retrospective, interrupted time-series analysis using a nationally representative,
privately-insured population from 1/1/2006-12/31/2011. Women ages 40–64 enrolled for $1 month were included. The
primary outcome was receipt of screening mammography, identified using administrative claims-based algorithms. Time-
series regression models were estimated to determine the effect of the guideline change on screening mammography rates.
5.5 million women ages 40–64 were included. A 1.8 per 1,000 women (p = 0.003) decrease in monthly screening
mammography rates for 40–49 year-old women was observed two months following the guideline change; no initial effect
was seen for 50–64 year-old women. However, two years following the guideline change, a slight increase in screening
mammography rates above expected was observed in both age groups.
Conclusions: We detected a modest initial drop in screening mammography rates in women ages 40–49 immediately after
the 2009 USPSTF guideline followed by an increase in screening rates. Unfavorable public reactions and release of
conflicting statements may have tempered the initial impact. Renewal of the screening debate may have brought
mammography to the forefront of women’s minds, contributing to the observed increase in mammography rates two years
after the guideline change. This pattern is unlikely to reflect informed choice and underscores the need for improved
translation of evidence-based care and guidelines into practice.
Citation: Wang AT, Fan J, Van Houten HK, Tilburt JC, Stout NK, et al. (2014) Impact of the 2009 US Preventive Services Task Force Guidelines on Screening
Mammography Rates on Women in Their 40s. PLoS ONE 9(3): e91399. doi:10.1371/journal.pone.0091399
Editor: James Coyne, University of Pennsylvania, United States of America
Received September 3, 2013; Accepted February 10, 2014; Published March 11, 2014
Copyright:  2014 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Small Grants Program sponsored by the Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: shah.nilay@mayo.edu
Introduction
In November 2009, the United States Preventive Services Task
Force (USPSTF) issued updated screening mammography guide-
lines which recommended ‘‘against routine screening mammog-
raphy in women aged 40 to 49 years (C recommendation) [1],’’
marking a major change from their previous recommendation of
routine screening mammography every 1 to 2 years starting at age
40. In December 2009, this wording was revised to ‘‘the decision
to start regular, biennial screening mammography before the age
of 50 years should be an individual one and take patient context
into account, including the patient’s values regarding specific
benefits and harms [1].’’ This guideline shift triggered an intense
national discussion with vociferous dissent from the public as well
as physicians, and prompted many professional organizations
including the American Cancer Society to reaffirm their differing
positions on screening mammography [2].
Given the renewed debate around the benefits and harms of
mammography in women in their 40s and the wide spectrum of
responses and reactions to the guidelines both among the public,
health care professionals and organizations, we aimed to
determine to what extent the updated USPSTF guidelines affected
the utilization of screening mammography among women in their
40s.
Methods
Ethics statement
This study was deemed exempt by Mayo Clinic Institutional
Review Board. Data are from the IMS LifeLink Health Plan
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Claims Database provided by IMS Health (www.imshealth.com)
and is hosted at the Mayo Clinic, Rochester, MN. The data was
de-identified by IMS before it was made accessible to Mayo Clinic.
The data are provided to the Mayo Clinic through a data use
agreement from IMS Health and thus we cannot share data.
Researchers would be able to obtain data directly from IMS
Health through a data use agreement and licensing fees.
Study sample
We conducted an interrupted time-series analysis utilizing
administrative data from the IMS LifeLink Health Plan Claims
Database (formerly PharMetrics; Danbury, CT) to evaluate the
impact of the USPSTF guidelines on screening mammography
rates. This longitudinal, patient-level database is one of the largest
integrated claims databases for commercial insurance in the US
and contains medical and pharmaceutical claims data for more
than 80 million members from over 100 health plans, including
both traditional and managed care plans [3]. It has been shown to
be nationally representative of the commercially insured US
population in various demographic measures including geographic
region [4]. The database provides basic demographic information,
administrative information related to the receipt of medical care
including medical diagnoses using ICD-9 (International Classifi-
cation of Diseases, 9th revision) coding system, and procedure
codes, using the CPT-4 (Current Procedural Terminology-4)
system.
The study sample included women aged 40 to 64 years old with
at least 1-month of enrollment in the IMS LifeLink database from
January 1, 2006 to December 31, 2011. Women 65 and older
were excluded from the study because the IMS LifeLink database
does not fully capture Medicare data. The start date of January
2006 was chosen in order to account for possible effects of the
recent economic recession and because it offers almost four years
of data prior to the USPSTF breast screening recommendations to
establish an adequate baseline and secular trend. The end date of
December 2011 was chosen in order to detect not only the short-
term impact but also the longer-term effect of the USPSTF
update. The six-year timeframe also allowed for proper evaluation
of seasonal fluctuations for mammography utilization. To
strengthen the comparison, we examined rates of screening pap
smears and tetanus immunizations to account for trends in
preventive behavior as a control group.
Identification of screening mammograms
Previous studies have developed and validated algorithms for
identifying screening mammograms using claims data [5,6]. Based
on these studies, we developed claims-based algorithms to
determine the number of screening mammograms per month
(Figure 1). Codes for both screening and diagnostic mammograms
were included in the algorithm as coding may not be reliable for
differentiating between screening and diagnostic mammograms
[7]. We also identified the number of enrollees for each month
from January 2006 to December 2011. Mammograms were
identified using HEDIS (Healthcare Effectiveness Data and
Information Set) and included CPT codes (76090, 76091,
76092, 77055, 77056, 77057) and ICD-9 diagnosis codes for
screening mammography (V76.11, V76.12). If there were dupli-
cate claims, more than one mammogram billed for the same
woman on the same day, this was counted as one mammogram.
Our outcome measure was defined as the monthly screening
mammography rate per 1,000 women. Mammography rates were
calculated on a monthly basis by dividing the number of screening
mammograms performed in a particular month divided by the
total number of eligible women in that month. This rate was
calculated overall and then stratified by age group (40–49 years,
50–64 years). Age was calculated based on the service year, thus
women moved from one age group to the other the year they
turned 50.
Statistical analysis
We used an interrupted time-series approach with segmented
linear regression models [8] to estimate the change in trends of
monthly screening mammography rates per 1,000 women for age
group 40–49 and 50–64 separately (Text S1. Statistical Appendix).
We defined two time segments: a baseline period (January 2006 to
October 2009) and a post-USPSTF update period (November
Figure 1. Screening algorithm used to identify screening mammograms. ICD-9, International Classification of Diseases, 9th revision; CPT,
Current Procedural Terminology.
doi:10.1371/journal.pone.0091399.g001
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2009 to December 2011). The models include a constant term to
estimate the mammography rate at baseline, a linear time trend,
and an indicator for the post-USPSTF update period (0:before
update, 1:after update). The impact of the USPSTF update is
estimated by the regression coefficient of the indicator variable,
which represents a level shift in the rate of mammography
screening at the time of the USPSTF update. Mammography
screening rates at two years after the update were estimated by
fitting the time series models to the observed monthly rates of
mammography screening. These observed rates were compared to
expected rates. Expected rates were calculated by using the
baseline trend prior to the guideline change to predict rated
through December 2011. Strong seasonal fluctuations were
adjusted by including an autoregressive error of the order of
12 months. Models were fit using SAS PROC AUTOREG using
SAS version 9.2 (SAS Institute Inc., Cary, NC). Given that the
intervention of interest was a guideline change which may have a
lagged effect, compared to a policy change, which may have a
more immediate effect, we used a 2-month post guideline period to
assess for the immediate impact of the guideline. Sensitivity
analyses with alternate number and cut-off dates of time periods
and accounting for effects of the economic recession were also
planned (Text S2. Sensitivity Analyses).
Results
The IMS LifeLink database included 11.4 million unique
women during this timeframe. Of these, 5,514,038 women met
eligibility criteria, 2,177,343 women in the 40–49 age group and
3,336,695 women in the 50–64 age group. The average baseline
monthly screening mammography rate from January 1, 2006 to
October 31, 2009 was 34.2 per 1,000 enrolled women per month
in the 40–49 age group and 42.9 per 1,000 enrolled women per
month in the age 50–64 age group.
Screening mammography rates in the 40 to 49 age
group
Based on the projected trend post-guideline change, we found
an initial 1.8 per 1,000 (p= 0.003) enrolled women per month
decrease in screening mammography rates in the 40–49 age group
two months after the update (Table 1, Figure 2). During the two-
year period following the guideline update, the screening
mammography rate in the 40–49 age group increased at a rate
of 0.09 per 1000 women per month (p,0.017). By December
2011, the observed screening mammography rate was 31.9 per
1000 women per month compared to the predicted rate of 25.4
per 1000 women per month based on the screening mammogra-
phy trend prior to the update. Changing the defined cut-off dates
for the post-guideline change period did not alter our results
(TextS2. Sensitivity Analyses). In comparison, there was no
significant change in Pap smear rates during the initial two-month
period (Figure S1). Tetanus rates were also unchanged in this age
group.
Screening mammography rates in the 50 to 64 age
group
In contrast, there was no significant change detected in the
screening mammography rate in the 50–64 age group in the
immediate two-month period after the guideline change (Table 2,
Figure 2). By December 2011, the observed mammography
screening rate was 39.3 per 1000 women per month compared to
the predicted rate of 29.7 per 1000 women per month based on
the screening mammography trend prior to the update. There was
no significant change in pap smear rates during the initial two-
month period (Figure S1). Tetanus rates remained unchanged
among women 50–64.
Discussion
This is the first study to quantify the potential effects of the 2009
USPSTF breast cancer screening recommendations on screening
mammography among privately insured women. The recommen-
dations changed from routine screening mammography every 1–
2 years for women 40 and over to routine screening mammog-
raphy for women 50 and over and engaging in individualized
decision making for women ages 40–49 [1]. These new
recommendations are more aligned with international screening
practices, but differ from guidelines by other organizations in the
US. The initial impact on screening rates is consistent with the
context of the update. We detected a modest initial drop in
screening mammograms for women in the 40–49 age group,
consistent with a more substantial recommendation change for this
age group, compared to no impact on mammography rates in the
50–64 age group, reflecting the more subtle change from annual to
biennial screening mammography.
Two previous studies have estimated effects of the guideline
change using self-report data and found that the guidelines had no
effect on screening mammography rates [9,10]. However, self-
reported survey data is reported to be strongly upwardly biased
compared to administrative data [11].
Our results also allay concerns that the major recommendation
shift in the 40–49 age group would have a ripple effect, decreasing
screening mammography among women over 50. In fact, we
observed the converse; the guideline change was associated with
an increase in screening mammography rates during the two-year
period after the update in all age groups. This may be attributable
to the renewal of the screening mammography debate in women
ages 40–49, which has resulted in more intense and frequent
media coverage of mammography since the guidelines were
released. The increase in news coverage may have made screening
mammography more prominent in women’s minds and may have
served as a persistent reminder to get a mammogram.
Public resistance to the update, possibly fueled by negative
portrayal of the USPSTF guidelines in the media [12] and the
subsequent release of numerous conflicting guidelines, may have
hindered the translation of these recommendations into practice.
The American Cancer Society (ACS) immediately reaffirmed its
previous guidelines when the USPSTF update was released [2],
continuing to recommend routine annual screening mammogra-
phy for women ages 40–49 as did the National Comprehensive
Cancer Network (NCCN) [13]. The American College of
Surgeons officially supported the ACS guidelines in January
2010 [14]. The American College of Radiology and Society for
Breast Imaging released a joint statement in January 2010 [15]
and in August 2011, the American College of Obstetricians and
Gynecologists (ACOG) released guidelines both in agreement with
the ACS guidelines [16]. The American College of Physicians
2007 guidelines already reflected the sentiments of the updated
USPSTF recommendations [17].’’ Two organizations released
guidelines in alignment with USPSTF: American Academy of
Family Physicians in January 2010 and Kaiser Permanente Care
Management Institute in August 2010 [18]. Perhaps, the issuance
of multiple guidelines also had a similar effect as the constant
media coverage, placing screening mammography at the forefront
of patients and clinicians’ minds.
We found decreasing screening mammography rates from 2007
to early 2009 which coincide with the timing of the recent Great
Recession. Dorn et al has shown that the recent economic
Impact of USPSTF Update on Mammography Rates
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recession had a negative impact on colonoscopy screening rates
[19]. Screening mammography rates dipped beyond expected
with the effects of the recession in the months following the
guideline update for women ages 40–49 (November 2009) but
then began to increase for both age groups, surpassing expected
rates, which is likely in part attributable to the economic recovery.
The overall trends in screening mammography rates coincide
nicely with both the downward and upward trajectories of the
economic recession and recovery.
Women in their upper-40s may have become accustomed to
annual screening mammography prior to the update and could be
more resistant to adjusting screening practices than women
turning 40. To explore this further, we analyzed yearly screening
mammography rates by within smaller age groups, 40–42, 43–45,
and 46–49. We found that the screening patterns were similar for
43–45 and 46–49 year-old women, with a small drop after the
guidelines and then decreasing at a slower rate in the two-year
period following the guidelines. On the other hand, the 40–42 age
group showed a steeper decline immediately after the guidelines
and then increased over the subsequent two years. It is possible
that these younger women initially held off after the USPSTF
guidelines were released then changed their minds possibly due to
increased mammography coverage, conflicting guidelines, the
economic recovery or other factors.
For comparison purposes, we also looked at rates of other
screening tests and preventive care for this age group. We did not
detect any drop in cervical cancer screening rates after the
USPSTF breast cancer screening update, but we also saw a slight
Figure 2. Screening mammography rates before and after the US Preventive Services Task Force guideline change. The solid lines
represent the observed screening mammography rates in women ages 40–49 and 50–64 before and after the change in breast cancer screening
guidelines by the US Preventive Services Task Force in November 2009. The dotted lines represent the modeled expected screening mammography
rates in the respective age groups after the guideline change.USPSTF, United States Preventive Services Task Force.
doi:10.1371/journal.pone.0091399.g002
Table 1. Screening mammography utilization rates by age 40–49, 2006–2011.
Women ages 40–49 Estimate
Standard
Error 95% CI p-value
Baseline mammography screening rate (intercept) 34.24/1000
women
0.91 (32.46, 36.02) ,0.001
Change in screening rate in the 2-months after guideline release 21.81/1000
women
0.59 (22.96, 20.65) 0.003
Trend in monthly screening rate prior to the guideline release 20.12 0.02 (20.17, 20.08) ,0.001
Trend in monthly screening rate 2-years after the guideline release 0.09 0.04 (0.02, 0.16) 0.017
CI: Confidence interval.
doi:10.1371/journal.pone.0091399.t001
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increase in Pap rates over the following two years after the update.
This slight increase may be fueled by the same factors resulting in
increased screening mammography rates, including media cover-
age, economic recovery, and perhaps women getting Pap smears
when going in for mammograms. Cervical cancer screening
guidelines also underwent a change during this same time period;
ACOG updated guidelines online in November 2009 and in print
in December 2009. However, the major change in this update was
directed at women under 30 and over age 65 [20]. For women
aged 30–64, the recommendation was updated from every 2–
3 year pap smears to every 3 years, which is unlikely to affect our
study population. Tetanus vaccinations are for primary preven-
tion, which limits its usefulness to compare with screening
mammography, which is secondary prevention. Nonetheless,
tetanus vaccination rates remained unchanged from projected
during this timeframe.
Our study also has several limitations. First, like all time-series
analyses, our results are based on projected trends, thus the
strength of our findings relies on the soundness of the projection.
There are also limitations inherent to using administrative data.
Algorithms for differentiating screening from diagnostic mammo-
grams have not been validated for a database utilizing commer-
cially-based insurance plans. Nevertheless, our conservative
assumption favored a null effect. We were unable to determine
the effect of potential policy changes within insurance plans that
may have affected screening rates. Our study is also unable to
determine whether the decrease and then subsequent increase in
screening mammogram rates was motivated by patient or
physician’s preferences or additional unmeasured variables. Given
the nature of administrative claims data, we cannot determine
whether the decline occurred in women with the lowest breast
cancer risk. Furthermore, our study was based on privately-insured
women and may not translate to women with other types of health
insurance.
These findings demonstrate that the USPSTF update to breast
cancer screening guidelines in November 2009 did have a modest
initial impact on screening mammography rates for women ages
40–49, but not women 50–64. Unexpectedly, screening mam-
mography has increased beyond projected rates for both age
groups in the two-year period following the update. The observed
increase in mammography screening might reflect the effect of the
economic recovery, media coverage, pro-screening campaigns,
clinician advocacy at the point of care, or women’s preferences,
other factors or their combination. It certainly cannot reflect an
improvement in the evidence base in support of mammography in
this age group or a manifestation of informed patient preferences.
There is need for further investigation not only on delineating
benefits and risks of screening mammography for women ages 40–
49, but also for more research on how to translate this complex
body of evidence into practice, to enable women and their
clinicians to engage in effective shared decision making. The
events following the USPSTF release also indicate the need for this
organization to engage powerful players in ensuring that the signal
of their recommendations does not get loss in the strident noise of
advocates and pundits. While some may be pleased to see evidence
of an increase in mammography screening even among women in
their 40s, their enthusiasm should be tempered as we do not know
the value of such an increase: we do not know to what extent, if
any, the increase in screening mammography rates will result in a
detectable decrease in breast cancer morbidity and mortality.
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Table 2. Screening mammography utilization rates by age 50–64, 2006–2011.
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